Clinical Trials - April 6, 2016
Orphazyme’s Arimoclomol shows promise
Orphazyme has announced preclinical and clinical trial phase I/II data demonstrating that arimoclomol, an inducer of heat shock proteins, can ameliorate disease and improve muscle function in inclusion body myositis. The exciting findings are the result of a collaboration between researchers from University College London and University of Kansas and are being published this week in […]
Drug Development Pharma - March 4, 2015
Progress on Drug for Orphan Disease
Orphazyme, a Danish biotech company working on the development of orphan drugs, recently completed a new series B capital round of 20 million Euro. Kurma Partners and Idinvest Partners joined the existing investor syndicate of Novo A/S, Sunstone Capital and Aescap Venture. The company is working on Arimoclomol, the leading drug candidate for the treatment […]
Clinical Trials - January 12, 2015
Orphazyme Raises Funds for Trials
Danish biotech company Orphazyme raised a €20 million ($24 million US) B round to pay for its work on rare lysosomal storage disorders as it moves toward Phase II trials. Investors included Novo Nordisk’s venture arm. Orphazyme’s lead candidate, Orph002, is a treatment for Niemann-Pick disease type C (NPC), a rare disorder in which cholesterol […]
